OmniAb to Participate in Two Investor Conferences in September
OmniAb (NASDAQ: OABI) has announced its participation in two upcoming investor conferences in September. The company will be present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11 in New York City, where management will deliver a corporate presentation on September 10th at 2:30 p.m. Eastern Time. Additionally, OmniAb will take part in the Craig-Hallum Bioprocessing Virtual Conference on September 19th, featuring a fireside chat.
At both events, OmniAb's management team will engage in one-on-one meetings with investors, providing opportunities for direct interaction and discussions about the company's progress and future plans. These conferences offer valuable platforms for OmniAb to showcase its developments and connect with the investment community.
OmniAb (NASDAQ: OABI) ha annunciato la sua partecipazione a due conferenze per investitori che si terranno a settembre. L'azienda sarà presente alla 26ª Conferenza annuale globale sugli investimenti di H.C. Wainwright dal 9 all'11 settembre a New York, dove il management presenterà un intervento aziendale il 10 settembre alle 14:30 ora orientale. Inoltre, OmniAb parteciperà alla Conferenza virtuale sul bioprocessing di Craig-Hallum il 19 settembre, che prevede un colloquio informale.
In entrambe le occasioni, il team di gestione di OmniAb parteciperà a incontri individuali con gli investitori, offrendo opportunità per interazioni dirette e discussioni sui progressi dell'azienda e sui piani futuri. Queste conferenze rappresentano piattaforme preziose per OmniAb per mostrare i suoi sviluppi e connettersi con la comunità degli investitori.
OmniAb (NASDAQ: OABI) ha anunciado su participación en dos conferencias para inversores que se llevarán a cabo en septiembre. La compañía estará presente en la 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright del 9 al 11 de septiembre en Nueva York, donde la dirección realizará una presentación corporativa el 10 de septiembre a las 2:30 p.m. hora del este. Además, OmniAb participará en la Conferencia Virtual de Bioprocesamiento de Craig-Hallum el 19 de septiembre, con un chat informal.
En ambos eventos, el equipo de gestión de OmniAb se involucrará en reuniones individuales con inversores, ofreciendo oportunidades para interacciones directas y discusiones sobre el progreso de la empresa y sus planes de futuro. Estas conferencias ofrecen plataformas valiosas para que OmniAb muestre sus desarrollos y se conecte con la comunidad inversora.
OmniAb (NASDAQ: OABI)는 9월에 열리는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참석하며, 경영진은 9월 10일 동부 시간으로 오후 2시 30분에 기업 발표를 진행합니다. 또한 OmniAb는 9월 19일 Craig-Hallum 바이오프로세싱 가상 컨퍼런스에 참여하여 담소를 나눌 예정입니다.
두 행사 모두에서 OmniAb의 경영진은 투자자와의 일대일 회의에 참여하여 회사의 진전과 미래 계획에 대해 직접 상호작용하고 논의할 기회를 제공합니다. 이러한 회의는 OmniAb가 자사의 발전을 선보이고 투자자 커뮤니티와 연결될 수 있는 소중한 플랫폼을 제공합니다.
OmniAb (NASDAQ: OABI) a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre. La société sera présente à la 26e Conférence Annuelle Globale sur les Investissements de H.C. Wainwright du 9 au 11 septembre à New York, où la direction fera une présentation d'entreprise le 10 septembre à 14h30 heure de l'Est. De plus, OmniAb participera à la Conférence Virtuelle sur le Bioprocessing de Craig-Hallum le 19 septembre, qui mettra en vedette un entretien en toute convivialité.
Lors des deux événements, l'équipe de direction d'OmniAb s'engagera dans des réunions individuelles avec les investisseurs, offrant des opportunités d'interaction directe et de discussions sur les progrès de l'entreprise et ses plans futurs. Ces conférences constituent des plateformes précieuses pour qu'OmniAb puisse présenter ses développements et se connecter avec la communauté des investisseurs.
OmniAb (NASDAQ: OABI) hat seine Teilnahme an zwei anstehenden Investorenkonferenzen im September bekannt gegeben. Das Unternehmen wird vom 9. bis 11. September in New York City bei der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright anwesend sein, wo das Management am 10. September um 14:30 Uhr Eastern Time eine Unternehmenspräsentation halten wird. Zudem wird OmniAb am 19. September an der Craig-Hallum Bioprocessing Virtuellen Konferenz teilnehmen, die ein informelles Gespräch umfasst.
Bei beiden Veranstaltungen wird das Managementteam von OmniAb Einzelgespräche mit Investoren führen, um direkte Interaktionen und Diskussionen über die Fortschritte des Unternehmens und seine Zukunftspläne zu ermöglichen. Diese Konferenzen bieten wertvolle Plattformen für OmniAb, um seine Entwicklungen zu präsentieren und mit der Investoren-Community in Kontakt zu treten.
- None.
- None.
- H.C. Wainwright 26th Annual Global Investment Conference, September 9-11 at the Lotte New York Palace Hotel. Management will deliver a corporate presentation on Tuesday, September 10th at 2:30 p.m. Eastern Time and will hold one-on-one meetings with investors.
- Craig-Hallum Bioprocessing Virtual Conference, September 19th. Management will participate in a fireside chat and will hold one-on-one and small group meetings with investors.
About OmniAb®
OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.
Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes.
OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.
For more information, please visit www.omniab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826074755/en/
OmniAb, Inc.
Kurt Gustafson
investors@OmniAb.com
X (Twitter) @OmniAbTech
(510) 768-7760
Source: OmniAb, Inc.
FAQ
When is OmniAb (OABI) presenting at the H.C. Wainwright Global Investment Conference?
Which investor conferences will OmniAb (OABI) attend in September 2023?
Will OmniAb (OABI) hold one-on-one meetings with investors at the September conferences?
What type of event will OmniAb (OABI) participate in at the Craig-Hallum conference?
